FDA drafts patient-centric CFS guidance

Share this article:

The experience of chronic fatigue syndrome may be a critical part of the FDA's approval process if new draft guidelines take hold. Regulatory Focus reports that the FDA is contemplating new rules, titled Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drugs for Treatment, that plays up the term “unmet medical need.”

RF says these three words could put potential treatments on the fast track. Yet the syndrome is a puzzler, in that tests can't detect the condition, which includes what the Centers for Disease Control and Prevention describes as overwhelming fatigue that can be accompanied by pain and impaired memory, among other symptoms.

RF notes that what makes the draft guidance significant is that the “FDA said it will be recommending some rather unique endpoints for CFS treatments,” including patient-reported symptoms and reliable outcome data.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.